MyFinsight
Home
Blog
About
Proceeds from issuance of
convertible notes payable
$1,245,000
Proceeds from issuance of
convertible notes payable -...
$115,000
(-88.44%↓ Y/Y)
Net cash provided by
financing activities
$1,291,178
(-16.31%↓ Y/Y)
Effect of exchange
rates on cash and...
$103
(-76.70%↓ Y/Y)
Canceled cashflow
$68,822
Net increase
(decrease) in cash and...
$933,032
(1373.68%↑ Y/Y)
Canceled cashflow
$358,249
Repayment of short-term
note payable
$68,822
(145.24%↑ Y/Y)
Stock-based compensation
$305,944
(-51.98%↓ Y/Y)
Other accrued
expenses
$133,316
(-70.24%↓ Y/Y)
Accounts payable
$116,657
(-42.95%↓ Y/Y)
Accrued interest
$49,213
(-54.49%↓ Y/Y)
Prepaid expenses and
other current assets
-$24,533
(92.68%↑ Y/Y)
Non-cash operating lease
expense
$12,112
(-50.81%↓ Y/Y)
Depreciation
$466
(-50.00%↓ Y/Y)
Net cash used in
operating activities
-$358,249
(77.84%↑ Y/Y)
Canceled cashflow
$642,241
Net loss
-$988,716
(67.19%↑ Y/Y)
Operating lease liability
-$11,774
(53.46%↑ Y/Y)
Back
Back
Cash Flow
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
source: myfinsight.com